119020-06-3

Basic information

• Product Name: 1-N-CBZ-2-CYANOPYRROLIDINE
• Synonyms: 2-CYANO-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-N-CBZ-2-CYANOPYRROLIDINE;1-N-Cbz-2-cycanopyrrolidine;1-Cbz-2-cyanopyrrolidine;1-Z-2-cyanopyrrolidine
• CAS NO: 119020-06-3
• Molecular Formula: C₁₃H₁₄N₂O₂
• Molecular Weight: 230.26
• Mol File: 119020-06-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 403.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -5.02±0.40(Predicted)
• CAS DataBase Reference: 1-N-CBZ-2-CYANOPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-CBZ-2-CYANOPYRROLIDINE(119020-06-3)
• EPA Substance Registry System: 1-N-CBZ-2-CYANOPYRROLIDINE(119020-06-3)

Safety Data

• Hazardous Substances Data: 119020-06-3(Hazardous Substances Data)

Usage

General Description

1-N-CBZ-2-CYANOPYRROLIDINE, also known as N-Carbobenzyloxy-2-cyanopyrrolidine, is a chemical compound with the molecular formula C15H19N3O2. It is a white to off-white solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. 1-N-CBZ-2-CYANOPYRROLIDINE is a derivative of pyrrolidine and contains a cyano group, as well as a carbobenzyloxy (CBZ) group, which makes it useful for protecting amines during chemical reactions. 1-N-CBZ-2-CYANOPYRROLIDINE is known for its use in the synthesis of various pharmaceuticals, including antiviral and antitumor agents. It is also commonly used as a building block in the production of other organic compounds.

Upstream product

• 93188-01-3 2-(aminocarbonyl)-1-pyrrolidinecarboxylic acid, phenylmethyl ester 
• 172876-96-9 3-oxo-1λ³-benzo[d][1,2]iodaoxole-1(3H)-carbonitrile 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 506-68-3 bromocyane 
• 506-78-5 cyanogen iodide 
• 24224-99-5 benzenesulfonyl cyanide 
• 19158-51-1 P-toluenesulfonyl cyanide 
• 25070-74-0 1-benzyloxycarbonylpyrrolidine 
• 501-53-1 benzyl chloroformate 
• 22821-76-7 4-(methylsulfonyl)benzonitrile 

Downstream Products

• 888314-28-1 2-ethoxycarbonimidoyl-pyrrolidine-1-carboxylic acid benzyl ester hydrochloride 

Relevant articles and documents

Decarboxylative Cyanation of Aliphatic Carboxylic Acids via Visible-Light Flavin Photocatalysis

An operationally simple method is disclosed for the decarboxylative cyanation of aliphatic carboxylic acids at room temperature. Riboflavin tetraacetate, which is an inexpensive organic photocatalyst, promotes the oxidation of carboxylic acids upon visible-light activation. After decarboxylation, the generated radicals are trapped by TsCN, yielding the desired nitriles without any further additive, in a redox-neutral process. Importantly, this protocol can be adapted to flow conditions.

Room temperature decarboxylative cyanation of carboxylic acids using photoredox catalysis and cyanobenziodoxolones: a divergent mechanism compared to alkynylation

The one-step conversion of aliphatic carboxylic acids to the corresponding nitriles has been accomplished via the merger of visible light mediated photoredox and cyanobenziodoxolones (CBX) reagents. The reaction proceeded in high yields with natural and non-natural α-amino and α-oxy acids, affording a broad scope of nitriles with excellent tolerance of the substituents in the α position. The direct cyanation of dipeptides and drug precursors was also achieved. The mechanism of the decarboxylative cyanation was investigated both computationally and experimentally and compared with the previously developed alkynylation reaction. Alkynylation was found to favor direct radical addition, whereas further oxidation by CBX to a carbocation and cyanide addition appeared more favorable for cyanation. A concerted mechanism is proposed for the reaction of radicals with EBX reagents, in contrast to the usually assumed addition elimination process.

INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS

The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W' are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention